ESSA Pharma (EPIX) announces that its Securityholders have approved the acquisition of all of the issued and outstanding common shares of the Company by XenoTherapeutics Inc., a non-profit biotechnology company, by way of a statutory plan of arrangement at the special meeting of Securityholders held today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPIX:
- ESSA Pharma Faces Class Action Lawsuit in California
- ESSA Pharma Receives Court Approval for Acquisition
- Essa Pharma provides update on combination agreement with Xeno
- ESSA Pharma Amends Agreement with XenoTherapeutics, Adjusts Shareholder Terms
- Essa Pharma amends business combination agreement with XenoTherapeutics